Failings Of Clinical Trials, Adaptive Pathways Dominate NGO Conference
Speakers at a conference organized by Health Action International highlighted ongoing concerns over the commercial nature of clinical trials, the growing trend to conduct trials in low and middle income countries, and perceived failings of the European Medicines Agency’s adaptive pathways initiative.
You may also be interested in...
The European Medicines Agency has dismissed a call to stop accepting applications for its adaptive pathways program until it has better evidence on how to use real-world data.
The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.
As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.